Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Louise Nielung¹, Merete Hetland², Lone Skov³, Hans Albert Frandsen⁴, Lene Dreyer⁵ and Bente Glintborg⁶, ¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, ⁴Patient Partner, Frederiksberg, Denmark, ⁵Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, ⁶DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
Abstract Number: 2278 • ACR Convergence 2024
Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study
Olga Tsyruk¹, Marina Birck², Sasha Bernatsky², Luck Lukusa³, Denis Choquette⁴, Gilles Boire⁵ and Walter Maksymowych⁶, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rhumadata™, Montreal, QC, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
Abstract Number: 2327 • ACR Convergence 2024
Differential Quantitative Profile of Myeloid Derived Suppressor Cells and Monocyte Subsets Relate to Clinical Phenotype and Disease Activity in Psoriatic Arthritis Patients
Jennifer Balderas Miranda¹, Jiram Torres Ruiz², Guillermo Guaracha Basañez³, Virginia Pascual Ramos⁴, Beatriz Alcalá-Carmona⁵, Yatzil Reyna-Juárez⁵, María José Ostos-prado⁵, Nancy R Mejía-Domínguez⁵, Guillermo Juarez-Vega⁶ and Diana Gomez-martin⁷, ¹Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ²INCMNSZ, Mexico, Federal District, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ⁶Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁷INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: The innate immune system not only participates in PsA pathogenesis but may also counteract with immunomodulatory elements. Proinflammatory and repairing roles according to monocyte…
Abstract Number: 2344 • ACR Convergence 2024
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt Jürgens⁶, Rasho Rashkov⁷, Barbara Schulz⁸, Weibin Bao⁹, Piotr Jagiello¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ²Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³PRIVATE PRACTICE, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁵CHR ORLEANS, ORLEANS, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸GKM Gesellschaft für Therapieforschung mbH, Lessingstrasse, Munchen, Germany, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ¹¹Health Care - NHS, Norwich, United Kingdom
Background/Purpose: Real-world data on long-term use of secukinumab complements clinical trial findings by providing insights from diverse patients in routine clinical settings. SERENA (CAIN457A3403) was…
Abstract Number: 2573 • ACR Convergence 2024
Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
Athimalaipet Ramanan¹, Nicolino Ruperto², Ivan Foeldvari³, Gabriel Vega Cornejo⁴, Stuart Keller⁵, Rona Wang⁵, Joana Araújo⁵, Maja Hojnik⁶, Priyanka Sen⁵, Ketan Marulkar⁵ and PIERRE QUARTIER⁷, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²IRCCS Giannina Gaslini, Genova, Italy, ³Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁴CREA de Guadalajara SC., Guadalajara, Mexico, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Co., Indianapolis, IN, ⁷Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Juvenile psoriatic arthritis (JPsA) and enthesitis-related-arthritis (ERA) are 2 categories of Juvenile Idiopathic Arthritis (JIA) according to the International League of Associations for Rheumatology…
Abstract Number: 0220 • ACR Convergence 2024
Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis
Otto Olivas-Vergara¹, Raquel Largo², Lina Martínez-Estupiñán³, Fredeswinda Romero-Bueno⁴, Olga Sánchez-Pernaute³, Javier R. Godo³, Maria del Carmen Fariña-Sabaris⁵, Belen Ruffin Vicente⁵, Carmen Herencia⁶, Aránzazu Mediero², Agustina Criado Alcazar⁷, Pablo E. Borges¹, Sheila Recuero-Díaz¹, Andrea Alvear-Torres³, Amalia Gil³, Antía García-Fernández³, Ana Elena Hoyo Fernandez⁸, M. Isabel Sanchez-Barba⁸, M. Belen Ortega Trompeta⁸, Cristina Vazquez-Carballo⁹, Gabriel Herrero-Beaumont³ and ESPERANZA NAREDO¹⁰, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, Madrid, Spain, ³Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁴Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁵Department of Dermatology.Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ⁶Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz, M, Spain, ⁷Primary Care..Centro de Salud Paseo Imperial, Madrid, Spain, ⁸Primary Care.Centro de Salud Paseo Imperial, Madrid, Spain, ⁹Joint and Bone Research Unit. IIS-Fundación Jiménez Díaz. Autonomous University of Madrid, Madrid, Spain, ¹⁰Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: The primary objective of this prospective, longitudinal, observational study was to evaluate the predictive value of ultrasound (US)-detected elementary lesions of dactylitis together with…
Abstract Number: 0583 • ACR Convergence 2024
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Alexis Ogdie¹, Philip Mease², Francois Nantel³, Frederic Lavie⁴, Mohamed Sharaf⁵, Emmanouil Rampakakis⁶, Helena Marzo-Ortega⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Nantel MedSci Consult, Montreal, QC, Canada, ⁴Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸Sorbonne Université, Paris, France
Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
Abstract Number: 1229 • ACR Convergence 2024
Frequency of Fibromyalgia Using Validated Measures in a Sample of Patients with Psoriatic Arthritis and Impact on Disease: A Cross-Sectional Multinational Study
avin maroof¹, Nelly Ziade², Lina El Kibbi³, Bassel Elzorkany⁴, Nizar Ani⁵, ASAL ADNAN RIDHA⁶, Faiq Gorial⁷, NABAA IHSAN JAWAD AWADH⁸, Nada Al Chama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Mohamed Abdulla Hannawi¹², Suad Hannawi¹³, Saed Atawnah¹⁴, HUSSEIN HALABI¹⁵, Manal Al-Mashaleh¹⁶, Ahmed Abogamal¹⁷, Rachid Bahiri¹⁸, Sahar Saad¹⁹, maha sabkar²⁰, Krystel Aouad²¹, Laure Gossec²², Ihsane Hmamouchi²³, nabaa abbas²⁴, Elyes Bouajina²⁵, Laila Aljazye²⁶ and Laila ayoub²⁷, and ArLAR-ARCH group, ¹University of Kurdistan Hawler, Erbil, Iraq, ²Saint-Joseph University, Beirut, Lebanon, ³Division of rheumatology / Department of Medicine / Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Private (BZRC), Cairo, Egypt, ⁵Baghdad College of Medicine, Baghdad, Iraq, ⁶Baghdad Teaching Hospital, baghdad, Iraq, ⁷Rheumatology Unit/Department of Medicine/ College of Medicine/ University of Baghdad, Baghdad, Iraq, ⁸Baghdad Teaching Hospital / Medical City, Baghdad, Iraq, ⁹Rheumatology Department / Ebn Al Nafiss Hospital / Damascus, Damascus, Syria, ¹⁰Djillali Bounaama university hospital, Algiers, Algeria, ¹¹The University of Jordan, amman, Jordan, ¹²Rheymatology Department / Emirate Health Services / Dubai, Dubai, United Arab Emirates, ¹³Ministry of Health and Prevention, Dubai, United Arab Emirates, ¹⁴Al-Quds University / Alahli Hospital / Hebron ,Palestine, Hebron, Palestinian Territories, ¹⁵King Faisal Specialist Hospital / Jeddah, Jeddah, Saudi Arabia, ¹⁶Royal Medical Services, Amman, Jordan, ¹⁷Dr. Sliman Al Habib Hospital / Al-Azhar Faculty of Medicine, Dubai, United Arab Emirates, ¹⁸El Ayachi Hospital / Medical University Hospital / Rabat, Rabat, Morocco, ¹⁹King Hamad University Hospital / Assiut Medical School of Egypt, Al Sayh, Bahrain, ²⁰King Hamad university Hospital, Arad, Bahrain, ²¹Saint George Hospital University Medical Center, Beirut, Lebanon, ²²Sorbonne Université, Paris, France, ²³Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ²⁴Baghdad teaching hospital, Medical city, Baghdad, Iraq, Baghdad, Iraq, ²⁵Farhat Hached Hospital of Sousse, Tunisia, Sousse, Tunisia, ²⁶Tripoli / Libya, Tripoli, Libya, ²⁷Rheumatology unit, department of internal medicine, Tripoli Central Hospital. Faculty of Medicine, University of Tripoli, Libya, Tripoli, Libya
Background/Purpose: Fibromyalgia (FM), a chronic pain disorder, is more prevalent in psoriatic arthritis (PsA) patients, impacting quality of life and potentially leading to unnecessary treatment escalation. Cultural factors may…
Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease¹, Ruizhi Zhao², Shannon Ferrante³, Natalie J. Shiff⁴, Pavithra Srinivas⁵, Soumya Chakravarty⁶ and Jessica A Walsh⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs LLC, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 2311 • ACR Convergence 2024
Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease Than Controls: A Retrospective Cohort Study in US Veterans
Natalie Anumolu¹, Ann Rosenthal¹, Katherine Sherman² and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee
Background/Purpose: CPPD has been shown to complicate other types of inflammatory arthritis such as rheumatoid arthritis. However, only a few studies have investigated the correlation…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
Abstract Number: 2345 • ACR Convergence 2024
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
Andre Lucas Ribeiro¹, Virginia Carrizo Abarza², Dafna Gladman³, Vinod Chandran⁴ and Lihi Eder⁵, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease where achieving remission remains challenging despite multiple approved biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).…
Abstract Number: 2581 • ACR Convergence 2024
Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Hejian Zou¹, Weiguo Wan², Yu Xue¹, Lingyun Sun³, Ning Zhang⁴, Haiying Chen⁵, Xiaofei Shi⁶, Shengyun Liu⁷, Lin Chen⁸, Xinmei Ma⁹, Hua Wei¹⁰, Zhenyu Jiang¹¹, Xiaomei Li¹², Hongtao Fan¹³, Hongbin Li¹⁴, Jingyang Li¹⁵, Rui Wu¹⁶, Guixiu Shi¹⁷, Jing Zhu¹⁸, Xiaodan Kong¹⁹, Yuewu Lu²⁰, Xiaojing Cui²¹, Qianning Zheng²¹, Xiaoyan Bai²² and Guangchao Dong²¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ³Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ⁴Shengjing Hospital Affiliated to China Medical University, Shenyang, China (People's Republic), ⁵The Third Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ⁸Jilin Province People's Hospital, Changchun, China (People's Republic), ⁹Zaozhuang Municipal Hospital, Zaozhuang, China (People's Republic), ¹⁰Subei People's Hospital of Jiangsu Province, Yangzhou, China (People's Republic), ¹¹The First Hospital of Jilin University, Changchun, China (People's Republic), ¹²The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (People's Republic), ¹³The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ¹⁴Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹⁵Zhuzhou Central Hospital, Zhuzhou, China (People's Republic), ¹⁶The Tirst Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China (People's Republic), ¹⁷The First Affilated Hospital of Xiamen University, Xiamen, China (People's Republic), ¹⁸Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), ¹⁹The Second Affiliated Hospital of Dalian Medical University, Dalian, China (People's Republic), ²⁰BeiJing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²¹Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China (People's Republic), ²²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing, China
Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…

« Previous Page
1
…
7
8
9
10
11
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].